Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma

Pigment Cell and Melanoma Research

Volumn 27, Issue 6, 2014, Pages 1117-1125

  Mar, Victoria J ^a,b,c   Wong, Stephen Q ^d   Logan, Aleksandra ^d   Nguyen, Trung ^a   Cebon, Jonathan ^e   Kelly, John W ^a   Wolfe, Rory ^b   Dobrovic, Alexander ^d,e,f   Mclean, Catriona ^a   Mcarthur, Grant A ^c,d,f  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

BRAF; Melanoma metastasis; Melanoma progression; RAC1 expression; RAC1 immunoreactivity; RAC1 mutation

Indexed keywords

GUANOSINE TRIPHOSPHATASE; RAC1 PROTEIN; B RAF KINASE; BRAF PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; RAC1 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL FEATURE; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALE; MELANOMA; MIDDLE AGED; MITOSIS RATE; PREVALENCE; SKIN ULCER; AGED; AMINO ACID SUBSTITUTION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; LYMPH NODE; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; STATISTICAL MODEL; ULTRAVIOLET RADIATION;

AGED; AMINO ACID SUBSTITUTION; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GTP PHOSPHOHYDROLASES; HUMANS; LOGISTIC MODELS; LYMPH NODES; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RAC1 GTP-BINDING PROTEIN; ULTRAVIOLET RAYS;

EID: 84911428364     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12295     Document Type: Article

References (41)

1. Akhtar, N., and Hotchin, N.A. (2001). RAC1 regulates adherens junctions through endocytosis of E-cadherin. Mol. Biol. Cell 12, 847-862.
2. Akhtar, N., Hudson, K.R., and Hotchin, N.A. (2000). Co-localization of Rac1 and E-cadherin in human epidermal keratinocytes. Cell Adhes. Commun. 7, 465-476.
3. Broekaert, S.M., Roy, R., Okamoto, I. et al. (2010). Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res. 23, 763-770.
4. Campbell, A.D., Lawn, S., Mcgarry, L.C., Welch, H.C., Ozanne, B.W., and Norman, J.C. (2013). P-Rex1 cooperates with PDGFRbeta to drive cellular migration in 3D microenvironments. PLoS ONE 8, e53982.
5. Caramel, J., Papadogeorgakis, E., Hill, L. et al. (2013). A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 24, 466-480.
6. Chadee, D.N., Xu, D., Hung, G., Andalibi, A., Lim, D.J., Luo, Z., Gutmann, D.H., and Kyriakis, J.M. (2006). Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc. Natl Acad. Sci. USA 103, 4463-4468.
7. Dalton, L.E., Kamarashev, J., Barinaga-Rementeria Ramirez, I., White, G., Malliri, A., and Hurlstone, A. (2013). Constitutive RAC activation is not sufficient to initiate melanocyte neoplasia but accelerates malignant progression. J. Invest. Dermatol. 133, 1572-1581.
8. Davis, M.J., Ha, B.H., Holman, E.C., Halaban, R., Schlessinger, J., and Boggon, T.J. (2013). RAC1P29S is a spontaneously activating cancer-associated GTPase. Proc. Natl Acad. Sci. USA 110, 912-917.
9. Devitt, B., Liu, W., Salemi, R., Wolfe, R., Kelly, J., Tzen, C.Y., Dobrovic, A., and Mcarthur, G. (2011). Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 24, 666-672.
10. Edlundh-Rose, E., Egyhazi, S., Omholt, K., Mansson-Brahme, E., Platz, A., Hansson, J., and Lundeberg, J. (2006). NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 16, 471-478.
11. Fortin Ensign, S.P., Mathews, I.T., Symons, M.H., Berens, M.E., and Tran, N.L. (2013). Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression. Front. Oncol. 3, 241.
12. Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
13. Jaffe, A.B., and Hall, A. (2002). Rho GTPases in transformation and metastasis. Adv. Cancer Res. 84, 57-80.
14. Jakob, J.A., Bassett, R.L. Jr, Ng, C.S. et al. (2012). NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4014-4023.
15. Jordan, P., Brazao, R., Boavida, M.G., Gespach, C., and Chastre, E. (1999). Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene 18, 6835-6839.
16. Kamai, T., Yamanishi, T., Shirataki, H., Takagi, K., Asami, H., Ito, Y., and Yoshida, K. (2004). Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin. Cancer Res. 10, 4799-4805.
17. Kamai, T., Shirataki, H., Nakanishi, K., Furuya, N., Kambara, T., Abe, H., Oyama, T., and Yoshida, K. (2010). Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer. BMC Cancer 10, 164.
18. Kovacic, H.N., Irani, K., and Goldschmidt-Clermont, P.J. (2001). Redox regulation of human Rac1 stability by the proteasome in human aortic endothelial cells. J. Biol. Chem. 276, 45856-45861.
19. Krauthammer, M., Kong, Y., Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
20. Lambert, J.M., Lambert, Q.T., Reuther, G.W., Malliri, A., Siderovski, D.P., Sondek, J., Collard, J.G., and Der, C.J. (2002). Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat. Cell Biol. 4, 621-625.
21. LeBoit, P.E., Burg, G., Weedon, D., and Sarasin, A. (eds.) (2006). Skin tumors. In Pathology and Genetics. (Lyon, France: IARC Press), pp. 66-75.
22. Li, A., Ma, Y., Jin, M., Mason, S., Mort, R.L., Blyth, K., Larue, L., Sansom, O.J., and Machesky, L.M. (2012). Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism. J. Invest. Dermatol. 132, 2610-2621.
23. Lindsay, C.R., Lawn, S., Campbell, A.D. et al. (2011). P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun. 2, 555.
24. Liu, W., Dowling, J.P., Murray, W.K., Mcarthur, G.A., Thompson, J.F., Wolfe, R., and Kelly, J.W. (2006). Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch. Dermatol. 142, 1551-1558.
25. Machesky, L.M., and Sansom, O.J. (2012). Rac1 in the driver's seat for melanoma. Pigment Cell Melanoma Res. 25, 762-764.
26. Mar, V.J., Wong, S.Q., Li, J. et al. (2013). BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin. Cancer Res. 19, 4589-4598.
27. McFarland, C.D., Korolev, K.S., Kryukov, G.V., Sunyaev, S.R., and Mirny, L.A. (2013). Impact of deleterious passenger mutations on cancer progression. Proc. Natl Acad. Sci. USA 110, 2910-2915.
28. Monaghan-Benson, E., and Burridge, K. (2013). Mutant B-RAF regulates a Rac-dependent cadherin switch in melanoma. Oncogene 32, 4836-4844.
29. Nethe, M., and Hordijk, P.L. (2010). The role of ubiquitylation and degradation in RhoGTPase signalling. J. Cell Sci. 123, 4011-4018.
30. Ong, C.C., Jubb, A.M., Jakubiak, D. et al. (2013). P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J. Natl Cancer Inst. 105, 606-607.
31. Pan, Y., Bi, F., Liu, N., Xue, Y., Yao, X., Zheng, Y., and Fan, D. (2004). Expression of seven main Rho family members in gastric carcinoma. Biochem. Biophys. Res. Commun. 315, 686-691.
32. Patel, R.A., Liu, Y., Wang, B., Li, R., and Sebti, S.M. (2014). Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene 33, 550-555.
33. Pratilas, C.A., Taylor, B.S., Ye, Q., Viale, A., Sander, C., Solit, D.B., and Rosen, N. (2009). (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl Acad. Sci. USA 106, 4519-4524.
34. Ray, R.M., Vaidya, R.J., and Johnson, L.R. (2007). MEK/ERK regulates adherens junctions and migration through Rac1. Cell Motil. Cytoskelet. 64, 143-156.
35. Richter, A., Grieu, F., Carrello, A. et al. (2013). A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci. Rep. 3, 1659.
36. Sanz-Moreno, V., Gadea, G., Ahn, J., Paterson, H., Marra, P., Pinner, S., Sahai, E., and Marshall, C.J. (2008). Rac activation and inactivation control plasticity of tumor cell movement. Cell 135, 510-523.
37. Vial, E., Sahai, E., and Marshall, C.J. (2003). ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4, 67-79.
38. Viros, A., Fridlyand, J., Bauer, J., Lasithiotakis, K., Garbe, C., Pinkel, D., and Bastian, B.C. (2008). Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 5, e120.
39. Wang, Z., Pedersen, E., Basse, A., Lefever, T., Peyrollier, K., Kapoor, S., Mei, Q., Karlsson, R., Chrostek-Grashoff, A., and Brakebusch, C. (2010). Rac1 is crucial for Ras-dependent skin tumor formation by controlling Pak1-Mek-Erk hyperactivation and hyperproliferation in vivo. Oncogene 29, 3362-3373.
40. Wang, P., Chen, L., Zhang, J., Chen, H., Fan, J., Wang, K., Luo, J., Chen, Z., Meng, Z., and Liu, L. (2014). Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene 33, 514-524.
41. Woodcock, S.A., Rushton, H.J., Castaneda-Saucedo, E., Myant, K., White, G.R., Blyth, K., Sansom, O.J., and Malliri, A. (2010). Tiam1-Rac signaling counteracts Eg5 during bipolar spindle assembly to facilitate chromosome congression. Curr. Biol. 20, 669-675.